Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

The biometric process—run by Indian staff—involved standard fingerprinting and a photo. She stressed the importance of ...

The recent federal announcement of a freeze on projects that help states use their Medicaid programs to suit the needs of ...

Fred Alger Management, an investment management company, released its “Alger Mid Cap Focus Fund” second-quarter 2025 investor ...

A CBS/YouGov poll released Sunday found Trump’s approval rating at 42%, with disapproval at 58%. That approval compares with ...

Newly declassified records from the Office of the Director of National Intelligence, the CIA, and the Justice Department inspector general shed new light on how top Obama administration officials adva ...

The board will vote to select the new member on Monday. The new member will finish out a term that runs through the end of ...

An artificial intelligence agenda formed on the podcasts of Silicon Valley billionaires is now being set into U.S. policy as ...

The S&P 500 edged up 0.06% to close at a record high of 6,309.62 on Tuesday (July 22), marking its 11th record close of 2025.

A human rights tribunal has found that an employer’s failure to provide accommodation for an immunocompromised worker ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...